Our Story
Our Brands
Newsroom
Investors
Contact
TORONTO - RIV Capital Inc. (“RIV Capital” or the “Company”) (CSE: RIV) (OTC: CNPOF), a cannabis packaged goods company with a focus on establishing one of the strongest portfolios of brands in key strategic U.S. markets, will report its financial results for the first quarter ended June 30, 2022, after markets close on Monday, August 29, 2022. The Company’s unaudited condensed interim consolidated financial statements and management’s discussion and analysis for the quarter will be available on the Company’s profile on SEDAR at www.sedar.com and on the Company’s website at www.rivcapital.com/investors.
Following the release of its first quarter 2023 financial results, an audio-only recording of RIV Capital’s conference call will be available on the Company’s website at www.rivcapital.com/investors.
RIV Capital is building a leading cannabis packaged goods company, with a focus on establishing one of the strongest portfolios of brands in key strategic U.S. markets. Backed by in-house expertise and cannabis domain knowledge, RIV Capital aims to grow its own brands and partner with established U.S. cannabis operators and brands to bring them to new markets and build market share. RIV Capital established the foundational building blocks of its active U.S. strategy with the announced Etain Acquisition. Through its strategic relationship with The Hawthorne Collective, Inc. (“The Hawthorne Collective”), a subsidiary of The ScottsMiracle-Gro Company, RIV Capital is The Hawthorne Collective’s preferred vehicle for cannabis-related investments not under the purview of other ScottsMiracle-Gro subsidiaries.
SOURCE RIV Capital Inc.
For further information: Media: media@rivcapital.com
Investor Relations: ir@rivcapital.com
You can unsubscribe at any time by clicking on the unsubscribe link at the bottom of our emails. By entering your email, you are indicating your acceptance of our privacy policy and terms of use.
Please select how you would like to hear from RIV Capital:
By providing your personal information to us, you consent to our disclosure of this information to our service providers (and other third parties) as described in our privacy policy, including those that may be located outside of your jurisdiction of residence, for the purposes of processing your personal information on our behalf, providing services to us or to you, operating and hosting our website and business and for the other purposes described in our privacy policy.
We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.
Yes, I’m definitely at least twenty-one (21) years of age or am otherwise a qualified patient.